{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:05Z","timestamp":1787008565922,"version":"build-2736575974"},"reference-count":132,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":102,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse organisatie voor wetenschappelijk onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vici","award":["918.19.627"],"award-info":[{"award-number":["918.19.627"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>New treatments are needed to improve the prognosis of pneumococcal meningitis. We performed a systematic review on adjunctive treatments in animal models of pneumococcal meningitis in order to identify treatments with the most potential to progress to clinical trials. Studies testing therapy adjunctive to antibiotics in animal models of pneumococcal meningitis were included. A literature search was performed using Medline, Embase and Scopus for studies published from 1990 up to 17 February 2023. Two investigators screened studies for inclusion and independently extracted data. Treatment effect was assessed on the clinical parameters disease severity, hearing loss and cognitive impairment and the biological parameters inflammation, brain injury and bacterial load. Adjunctive treatments were evaluated by their effect on these outcomes and the quality, number and size of studies that investigated the treatments. Risk of bias was assessed with the SYRCLE risk of bias tool. A total of 58 of 2462 identified studies were included, which used 2703 experimental animals. Disease modelling was performed in rats (29 studies), rabbits (13 studies), mice (12 studies), gerbils (3 studies) or both rats and mice (1 study). Meningitis was induced by injection of Streptococcus pneumoniae into the subarachnoid space. Randomization of experimental groups was performed in 37 of 58 studies (64%) and 12 studies (12%) were investigator-blinded. Overall, 54 treatment regimens using 46 adjunctive drugs were evaluated: most commonly dexamethasone (16 studies), daptomycin (5 studies), complement component 5 (C5; 3 studies) antibody and Mn(III)tetrakis(4-benzoicacid)porphyrin chloride (MnTBAP; 3 studies). The most frequently evaluated outcome parameters were inflammation [32 studies (55%)] and brain injury [32 studies (55%)], followed by disease severity [30 studies (52%)], hearing loss [24 studies (41%)], bacterial load [18 studies (31%)] and cognitive impairment [9 studies (16%)]. Adjunctive therapy that improved clinical outcomes in multiple studies was dexamethasone (6 studies), C5 antibodies (3 studies) and daptomycin (3 studies). HMGB1 inhibitors, matrix metalloproteinase inhibitors, neurotrophins, antioxidants and paquinimod also improved clinical parameters but only in single or small studies. Evaluating the treatment effect of adjunctive therapy was complicated by study heterogeneity regarding the animal models used and outcomes reported. In conclusion, 24 of 54 treatment regimens (44%) tested improved clinically relevant outcomes in experimental pneumococcal meningitis but few were tested in multiple well-designed studies. The most promising new adjunctive treatments are with C5 antibodies or daptomycin, suggesting that these drugs could be tested in clinical trials.<\/jats:p>","DOI":"10.1093\/braincomms\/fcae131","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T12:57:31Z","timestamp":1712753851000},"source":"Crossref","is-referenced-by-count":4,"title":["Adjunctive treatments for pneumococcal meningitis: a systematic review of experimental animal models"],"prefix":"10.1093","volume":"6","author":[{"given":"Rutger","family":"Koning","sequence":"first","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience , 1100DD Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian A","family":"van Roon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience , 1100DD Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs C","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience , 1100DD Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-044X","authenticated-orcid":false,"given":"Diederik","family":"van de Beek","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience , 1100DD Amsterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"issue":"5","key":"2024062807261001300_fcae131-B1","doi-asserted-by":"crossref","first-page":"e1099","DOI":"10.1093\/cid\/ciaa1774","article-title":"Changing epidemiology of bacterial meningitis since introduction of conjugate vaccines: 3 decades of national meningitis surveillance in The Netherlands","volume":"73","author":"Koelman","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9854","key":"2024062807261001300_fcae131-B2","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(12)61186-6","article-title":"Advances in treatment of bacterial meningitis","volume":"380","author":"van de Beek","year":"2012","journal-title":"Lancet"},{"issue":"10306","key":"2024062807261001300_fcae131-B3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(21)00883-7","article-title":"Community-acquired bacterial meningitis","volume":"398","author":"van de Beek","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"2024062807261001300_fcae131-B4","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/jnnp.2006.110023","article-title":"Cognitive outcome in adults after bacterial meningitis","volume":"78","author":"Hoogman","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"2024062807261001300_fcae131-B5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1473-3099(15)00430-2","article-title":"Community-acquired bacterial meningitis in adults in The Netherlands, 2006\u201314: A prospective cohort study","volume":"16","author":"Bijlsma","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2024062807261001300_fcae131-B6","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.00008-11","article-title":"Pathogenesis and pathophysiology of pneumococcal meningitis","volume":"24","author":"Mook-Kanamori","year":"2011","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"2024062807261001300_fcae131-B7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/nrmicro.2016.178","article-title":"A journey into the brain: Insight into how bacterial pathogens cross blood\u2013brain barriers","volume":"15","author":"Coureuil","year":"2017","journal-title":"Nat Rev Microbiol"},{"issue":"12","key":"2024062807261001300_fcae131-B8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1473-3099(02)00450-4","article-title":"Pathogenesis and pathophysiology of pneumococcal meningitis","volume":"2","author":"Koedel","year":"2002","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2024062807261001300_fcae131-B9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/QCO.0b013e328337f49e","article-title":"New understandings on the pathophysiology of bacterial meningitis","volume":"23","author":"Koedel","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"2024062807261001300_fcae131-B10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40478-016-0297-4","article-title":"Pneumococcal meningitis: Clinical\u2013pathological correlations (MeninGene-Path)","volume":"4","author":"Engelen-Lee","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"5","key":"2024062807261001300_fcae131-B11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/infdis\/151.5.859","article-title":"The induction of meningeal inflammation by components of the pneumococcal cell wall","volume":"151","author":"Tuomanen","year":"1985","journal-title":"J Infect Dis"},{"issue":"3","key":"2024062807261001300_fcae131-B12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.clp.2010.05.004","article-title":"Meningitis in neonates: Bench to bedside","volume":"37","author":"Grandgirard","year":"2010","journal-title":"Clin Perinatol"},{"issue":"3","key":"2024062807261001300_fcae131-B13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1128\/CMR.00070-09","article-title":"Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis","volume":"23","author":"Brouwer","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"2024062807261001300_fcae131-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.femsim.2005.01.001","article-title":"Minimizing the release of proinflammatory and toxic bacterial products within the host: A promising approach to improve outcome in life-threatening infections","volume":"44","author":"Nau","year":"2005","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"6","key":"2024062807261001300_fcae131-B15","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1128\/AAC.01000-06","article-title":"Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall","volume":"51","author":"Stucki","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"2024062807261001300_fcae131-B16","first-page":"CD004405","article-title":"Corticosteroids for acute bacterial meningitis","volume":"2018","author":"Brouwer","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"20","key":"2024062807261001300_fcae131-B17","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJMoa021334","article-title":"European dexamethasone in adulthood bacterial meningitis study I. Dexamethasone in adults with bacterial meningitis","volume":"347","author":"de Gans","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"2024062807261001300_fcae131-B18","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(10)70023-5","article-title":"Adjunctive dexamethasone in bacterial meningitis: A meta-analysis of individual patient data","volume":"9","author":"van de Beek","year":"2010","journal-title":"Lancet Neurol"},{"issue":"20","key":"2024062807261001300_fcae131-B19","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1001\/jama.2013.280506","article-title":"Induced hypothermia in severe bacterial meningitis: A randomized clinical trial","volume":"310","author":"Mourvillier","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"2024062807261001300_fcae131-B20","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1473-3099(11)70055-X","article-title":"Slow initial beta-lactam infusion and oral paracetamol to treat childhood bacterial meningitis: A randomised, controlled trial","volume":"11","author":"Pelkonen","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2024062807261001300_fcae131-B21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/INF.0000000000000122","article-title":"Glycerol and acetaminophen as adjuvant therapy did not affect the outcome of bacterial meningitis in Malawian children","volume":"33","author":"Molyneux","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2024062807261001300_fcae131-B22","author":"Lobbestael","year":"2023"},{"issue":"1","key":"2024062807261001300_fcae131-B23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev."},{"issue":"1","key":"2024062807261001300_fcae131-B24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol."},{"key":"2024062807261001300_fcae131-B25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"2024062807261001300_fcae131-B26","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1128\/AAC.00674-12","article-title":"Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis","volume":"56","author":"Grandgirard","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"2024062807261001300_fcae131-B27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-018-1272-8","article-title":"Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis","volume":"15","author":"Muri","year":"2018","journal-title":"J Neuroinflammation."},{"issue":"7","key":"2024062807261001300_fcae131-B28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.00220-19","article-title":"Combining ceftriaxone with doxycycline and daptomycin reduces mortality, neuroinflammation, brain damage, and hearing loss in infant rat pneumococcal meningitis","volume":"63","author":"Muri","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"2024062807261001300_fcae131-B29","doi-asserted-by":"crossref","first-page":"108.e9\u2013","DOI":"10.1016\/j.cmi.2018.03.039","article-title":"Adjuvant non-bacteriolytic and anti-inflammatory combination therapy in pneumococcal meningitis: An investigation in a mouse model","volume":"25","author":"Klein","year":"2019","journal-title":"Clin Microbiol Infect."},{"issue":"7","key":"2024062807261001300_fcae131-B30","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1128\/IAI.01949-05","article-title":"Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis","volume":"74","author":"Meli","year":"2006","journal-title":"Infect Immun."},{"issue":"7","key":"2024062807261001300_fcae131-B31","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/CCM.0b013e3181a036c0","article-title":"Short-term rifampicin pretreatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis","volume":"37","author":"Spreer","year":"2009","journal-title":"Crit Care Med."},{"issue":"2","key":"2024062807261001300_fcae131-B32","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1212\/WNL.58.2.186","article-title":"Oxidative stress in bacterial meningitis in humans","volume":"58","author":"Kastenbauer","year":"2002","journal-title":"Neurology"},{"issue":"6","key":"2024062807261001300_fcae131-B33","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.pneurobio.2006.11.008","article-title":"Oxidative stress in pneumococcal meningitis: A future target for adjunctive therapy?","volume":"80","author":"Klein","year":"2006","journal-title":"Prog Neurobiol"},{"issue":"4","key":"2024062807261001300_fcae131-B34","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1086\/315048","article-title":"Role of peroxynitrite as a mediator of pathophysiological alterations in experimental pneumococcal meningitis","volume":"180","author":"Kastenbauer","year":"1999","journal-title":"J Infect Dis"},{"issue":"2","key":"2024062807261001300_fcae131-B35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0014-2999(01)01137-2","article-title":"Experimental meningitis in the rat: Protection by uric acid at human physiological blood concentrations","volume":"425","author":"Kastenbauer","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2024062807261001300_fcae131-B36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/315658","article-title":"Effects of clinically used antioxidants in experimental pneumococcal meningitis","volume":"182","author":"Auer","year":"2000","journal-title":"J Infect Dis"},{"issue":"2","key":"2024062807261001300_fcae131-B37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0006-8993(01)02164-3","article-title":"Reactive nitrogen species contribute to blood\u2013labyrinth barrier disruption in suppurative labyrinthitis complicating experimental pneumococcal meningitis in the rat","volume":"904","author":"Kastenbauer","year":"2001","journal-title":"Brain Res"},{"issue":"3","key":"2024062807261001300_fcae131-B38","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3109\/00016489509139334","article-title":"NG-methyl-L-arginine protects the guinea pig cochlea from the cytotoxic effects of pneumolysin","volume":"115","author":"Amaee","year":"1995","journal-title":"Acta Otolaryngol"},{"issue":"4","key":"2024062807261001300_fcae131-B39","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/ana.10684","article-title":"Meningitis-associated hearing loss: Protection by adjunctive antioxidant therapy","volume":"54","author":"Klein","year":"2003","journal-title":"Ann Neurol"},{"issue":"10","key":"2024062807261001300_fcae131-B40","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1128\/AAC.00148-13","article-title":"Adjunctive N-acetyl-L-cysteine in treatment of murine pneumococcal meningitis","volume":"57","author":"H\u00f6gen","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"2024062807261001300_fcae131-B41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0006-8993(01)02164-3","article-title":"Reactive nitrogen species contribute to blood\u2013labyrinth barrier disruption in suppurative labyrinthitis complicating experimental pneumococcal meningitis in the rat","volume":"904","author":"Kastenbauer","year":"2001","journal-title":"Brain Res."},{"issue":"1\u20132","key":"2024062807261001300_fcae131-B42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0014-2999(02)01980-5","article-title":"Pneumococcal meningitis in the rat: Evaluation of peroxynitrite scavengers for adjunctive therapy","volume":"449","author":"Kastenbauer","year":"2002","journal-title":"Eur J Pharmacol."},{"issue":"2","key":"2024062807261001300_fcae131-B43","first-page":"49","article-title":"Effect of new compound with antioxidant potential in the energy metabolism of adults rats after pneumococcal meningitis","volume":"7","author":"Barichello","journal-title":"Am J Pharmacol Toxicol."},{"issue":"5","key":"2024062807261001300_fcae131-B44","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.otohns.2004.03.046","article-title":"The effects of superoxide dismutase in gerbils with bacterial meningitis","volume":"131","author":"Ge","year":"2004","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"2024062807261001300_fcae131-B45","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1089\/ars.2009.2876","article-title":"Superoxide dismutase mimics: Chemistry, pharmacology, and therapeutic potential","volume":"13","author":"Batinic-Haberle","year":"2010","journal-title":"Antioxid Redox Signal"},{"issue":"13","key":"2024062807261001300_fcae131-B46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1359-6446(04)03139-3","article-title":"Catalytic antioxidants: A radical approach to new therapeutics","volume":"9","author":"Day","year":"2004","journal-title":"Drug Discov Today"},{"issue":"1","key":"2024062807261001300_fcae131-B47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"issue":"1","key":"2024062807261001300_fcae131-B48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","article-title":"The complement system","volume":"343","author":"Sarma","year":"2011","journal-title":"Cell Tissue Res"},{"issue":"10","key":"2024062807261001300_fcae131-B49","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1172\/JCI57522","article-title":"Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis","volume":"121","author":"Woehrl","year":"2011","journal-title":"J Clin Invest."},{"key":"2024062807261001300_fcae131-B50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-015-0372-y","article-title":"Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: A randomized controlled trial","volume":"12","author":"Kasanmoentalib","year":"2015","journal-title":"J Neuroinflammation."},{"key":"2024062807261001300_fcae131-B51","first-page":"1-0","article-title":"Mannose-binding lectin-associated serine protease 2 (MASP-2) contributes to poor disease outcome in humans and mice with pneumococcal meningitis","volume":"14","author":"Kasanmoentalib","year":"2017","journal-title":"J Neuroinflammation."},{"key":"2024062807261001300_fcae131-B52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-019-1675-1","article-title":"Complement factor H contributes to mortality in humans and mice with bacterial meningitis","volume":"16","author":"Kasanmoentalib","year":"2019","journal-title":"J Neuroinflammation."},{"issue":"1","key":"2024062807261001300_fcae131-B53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2119\/molmed.2013.00164","article-title":"The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases","volume":"20","author":"Magna","year":"2014","journal-title":"Mol Med"},{"key":"2024062807261001300_fcae131-B54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-immunol-030409-101323","article-title":"HMGB1 is a therapeutic target for sterile inflammation and infection","volume":"29","author":"Andersson","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"2024062807261001300_fcae131-B55","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/01.shk.0000225404.51320.82","article-title":"HMGB1 signals through toll-like receptor (TLR) 4 and TLR2","volume":"26","author":"Yu","year":"2006","journal-title":"Shock"},{"issue":"1","key":"2024062807261001300_fcae131-B56","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1073\/pnas.2434651100","article-title":"Reversing established sepsis with antagonists of endogenous high-mobility group box 1","volume":"101","author":"Yang","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"2024062807261001300_fcae131-B57","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1096\/fj.07-8770com","article-title":"Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats","volume":"21","author":"Liu","year":"2007","journal-title":"FASEB J"},{"issue":"6","key":"2024062807261001300_fcae131-B58","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/brain\/awt064","article-title":"High mobility group box 1 prolongs inflammation and worsens disease in pneumococcal meningitis","volume":"136","author":"H\u00f6hne","year":"2013","journal-title":"Brain"},{"key":"2024062807261001300_fcae131-B59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-017-0989-0","article-title":"Inhibition of DAMP signaling as an effective adjunctive treatment strategy in pneumococcal meningitis","volume":"14","author":"Masouris","year":"2017","journal-title":"J Neuroinflammation."},{"issue":"8","key":"2024062807261001300_fcae131-B60","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nri1418","article-title":"Matrix metalloproteinases as modulators of inflammation and innate immunity","volume":"4","author":"Parks","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2024062807261001300_fcae131-B61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1086\/313922","article-title":"Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: Association with blood\u2013brain barrier damage and neurological sequelae","volume":"31","author":"Leppert","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"2\u20133","key":"2024062807261001300_fcae131-B62","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0165-0173(01)00101-1","article-title":"Matrix metalloproteinases: Multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis","volume":"36","author":"Leppert","year":"2001","journal-title":"Brain Res Brain Res Rev"},{"issue":"9","key":"2024062807261001300_fcae131-B63","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/brain\/124.9.1734","article-title":"Inhibition of matrix metalloproteinases and tumour necrosis factor \u03b1 converting enzyme as adjuvant therapy in pneumococcal meningitis","volume":"124","author":"Leib","year":"2001","journal-title":"Brain"},{"issue":"4","key":"2024062807261001300_fcae131-B64","doi-asserted-by":"crossref","first-page":"489","DOI":"10.55782\/ane-2014-2011","article-title":"Efficacy of GM6001 as an adjuvant to ceftriaxone in a neonatal rat model of Streptococcus pneumoniae meningitis","volume":"74","author":"Liu","year":"2014","journal-title":"Acta Neurobiol Exp (Wars)."},{"issue":"4","key":"2024062807261001300_fcae131-B65","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrn1078","article-title":"Neurotrophins and their receptors: A convergence point for many signalling pathways","volume":"4","author":"Chao","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"2024062807261001300_fcae131-B66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fncel.2019.00363","article-title":"Brain-derived neurotrophic factor: A key molecule for memory in the healthy and the pathological brain","volume":"13","author":"Miranda","year":"2019","journal-title":"Front Cell Neurosci"},{"issue":"3\u20134","key":"2024062807261001300_fcae131-B67","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/08977194.2020.1864347","article-title":"A narrative review of brain-derived neurotrophic factor (BDNF) on cognitive performance in Alzheimer\u2019s disease","volume":"38","author":"Ismail","year":"2020","journal-title":"Growth Factors"},{"issue":"1","key":"2024062807261001300_fcae131-B68","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/08830738050200010801","article-title":"Neuroprotective effects of brain-derived neurotrophic factor (BDNF) on hearing in experimental pneumococcal meningitis","volume":"20","author":"Li","year":"2005","journal-title":"J Child Neurol."},{"key":"2024062807261001300_fcae131-B69","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s10072-014-1862-x","article-title":"The responsiveness of TrkB to exogenous BDNF in frontal cortex during antibiotic treatment of Streptococcus pneumoniae meningitis","volume":"35","author":"Song","year":"2014","journal-title":"Neurol Sci."},{"issue":"22","key":"2024062807261001300_fcae131-B70","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1523\/JNEUROSCI.5123-04.2005","article-title":"ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin","volume":"25","author":"Teng","year":"2005","journal-title":"J Neurosci"},{"issue":"8","key":"2024062807261001300_fcae131-B71","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nn1510","article-title":"Activation of p75NTR by proBDNF facilitates hippocampal long-term depression","volume":"8","author":"Woo","year":"2005","journal-title":"Nat Neurosci"},{"issue":"3","key":"2024062807261001300_fcae131-B72","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.celrep.2014.03.040","article-title":"proBDNF negatively regulates neuronal remodeling, synaptic transmission, and synaptic plasticity in hippocampus","volume":"7","author":"Yang","year":"2014","journal-title":"Cell Rep"},{"issue":"6","key":"2024062807261001300_fcae131-B73","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.7150\/thno.17666","article-title":"[18F]GE-180 PET detects reduced microglia activation after LM11A-31 therapy in a mouse model of Alzheimer\u2019s disease","volume":"7","author":"James","year":"2017","journal-title":"Theranostics"},{"issue":"22","key":"2024062807261001300_fcae131-B74","first-page":"4920","article-title":"A small molecule p75NTR ligand normalizes signalling and reduces Huntington\u2019s disease phenotypes in R6\/2 and BACHD mice","volume":"25","author":"Simmons","year":"2016","journal-title":"Hum Mol Genet"},{"key":"2024062807261001300_fcae131-B75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-021-02294-w","article-title":"Regulation of the p75 neurotrophin receptor attenuates neuroinflammation and stimulates hippocampal neurogenesis in experimental Streptococcus pneumoniae meningitis","volume":"18","author":"Zhang","year":"2021","journal-title":"J Neuroinflammation."},{"key":"2024062807261001300_fcae131-B76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-8-7","article-title":"Reduced spiral ganglion neuronal loss by adjunctive neurotrophin-3 in experimental pneumococcal meningitis","volume":"8","author":"Demel","year":"2011","journal-title":"J Neuroinflammation."},{"issue":"9","key":"2024062807261001300_fcae131-B77","doi-asserted-by":"crossref","first-page":"e0203228","DOI":"10.1371\/journal.pone.0203228","article-title":"The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis","volume":"13","author":"Fransen Pettersson","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"2024062807261001300_fcae131-B78","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pbio.1000097","article-title":"Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides","volume":"7","author":"Bjork","year":"2009","journal-title":"PLoS Biol"},{"issue":"3","key":"2024062807261001300_fcae131-B79","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1203\/01.PDR.0000079185.67878.72","article-title":"Dexamethasone aggravates hippocampal apoptosis and learning deficiency in pneumococcal meningitis in infant rats","volume":"54","author":"Leib","year":"2003","journal-title":"Pediatr Res."},{"issue":"3","key":"2024062807261001300_fcae131-B80","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1128\/AAC.02429-15","article-title":"Inhibition of hippocampal regeneration by adjuvant dexamethasone in experimental infant rat pneumococcal meningitis","volume":"60","author":"Bally","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"2024062807261001300_fcae131-B81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/173035","article-title":"Dexamethasone treatment reverses cognitive impairment but increases brain oxidative stress in rats submitted to pneumococcal meningitis","volume":"2011","author":"Barichello","year":"2011","journal-title":"Oxid Med Cell Longev."},{"issue":"11","key":"2024062807261001300_fcae131-B82","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1093\/brain\/awz222","article-title":"Targeting the complement system in bacterial meningitis","volume":"142","author":"Koelman","year":"2019","journal-title":"Brain"},{"issue":"6","key":"2024062807261001300_fcae131-B83","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jinf.2013.12.016","article-title":"Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis","volume":"68","author":"Mook-Kanamori","year":"2014","journal-title":"J Infect"},{"issue":"5","key":"2024062807261001300_fcae131-B84","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s00134-012-2792-9","article-title":"Delayed cerebral thrombosis in bacterial meningitis: A prospective cohort study","volume":"39","author":"Lucas","year":"2013","journal-title":"Intensive Care Med"},{"issue":"Suppl 3","key":"2024062807261001300_fcae131-B85","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.cmi.2016.01.007","article-title":"ESCMID guideline: Diagnosis and treatment of acute bacterial meningitis","volume":"22","author":"van de Beek","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2024062807261001300_fcae131-B86","first-page":"49","volume-title":"Janeway\u2019s immunobiology","author":"Murphy","year":"2017","edition":"9th ed"},{"issue":"1","key":"2024062807261001300_fcae131-B87","doi-asserted-by":"crossref","first-page":"e01755","DOI":"10.1128\/mBio.01755-17","article-title":"Complement C5a receptor 1 exacerbates the pathophysiology of N. meningitidis sepsis and is a potential target for disease treatment","volume":"9","author":"Herrmann","year":"2018","journal-title":"mBio"},{"issue":"10","key":"2024062807261001300_fcae131-B88","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1182\/blood-2003-03-0703","article-title":"Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis","volume":"102","author":"Sprong","year":"2003","journal-title":"Blood"},{"key":"2024062807261001300_fcae131-B89","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Mol Immunol"},{"issue":"12","key":"2024062807261001300_fcae131-B90","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2024062807261001300_fcae131-B91","doi-asserted-by":"crossref","first-page":"100995","DOI":"10.1016\/j.blre.2022.100995","article-title":"Complement activation in COVID-19 and targeted therapeutic options: A scoping review","volume":"57","author":"Lim","year":"2023","journal-title":"Blood Rev"},{"issue":"12","key":"2024062807261001300_fcae131-B92","doi-asserted-by":"crossref","first-page":"e764","DOI":"10.1016\/S2665-9913(20)30341-6","article-title":"Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): An exploratory, open-label, phase 2 randomised controlled trial","volume":"2","author":"Vlaar","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"2024062807261001300_fcae131-B93","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","article-title":"Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"10","author":"Vlaar","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2024062807261001300_fcae131-B94","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1128\/AAC.00812-09","article-title":"Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis","volume":"54","author":"Grandgirard","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2024062807261001300_fcae131-B95","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1128\/AAC.01014-06","article-title":"Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis","volume":"51","author":"Grandgirard","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2024062807261001300_fcae131-B96","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.00943-09","article-title":"Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae","volume":"54","author":"Henken","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"2024062807261001300_fcae131-B97","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1086\/533441","article-title":"Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia","volume":"46","author":"Pertel","year":"2008","journal-title":"Clin Infect Dis."},{"key":"2024062807261001300_fcae131-B98","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13756-016-0158-8","article-title":"Daptomycin-induced eosinophilic pneumonia\u2014A systematic review","volume":"5","author":"Uppal","year":"2016","journal-title":"Antimicrob Resist Infect Control"},{"issue":"6","key":"2024062807261001300_fcae131-B99","first-page":"362","article-title":"Early onset rhabdomyolysis and acute renal failure associated with the administration of daptomycin. A case report and literature review","volume":"53","author":"Ramirez-Martin","year":"2018","journal-title":"Rev Esp Geriatr Gerontol"},{"issue":"5","key":"2024062807261001300_fcae131-B100","doi-asserted-by":"crossref","first-page":"106770","DOI":"10.1016\/j.ijantimicag.2023.106770","article-title":"Daptomycin for the treatment of acute bacterial meningitis: A narrative review","volume":"61","author":"Jaber","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"2024062807261001300_fcae131-B101","doi-asserted-by":"crossref","first-page":"e003968","DOI":"10.1161\/JAHA.116.003968","article-title":"Effectiveness of N-acetylcysteine for the prevention of contrast-induced nephropathy: A systematic review and meta-analysis of randomized controlled trials","volume":"5","author":"Xu","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"2024062807261001300_fcae131-B102","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jcf.2014.08.008","article-title":"Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial","volume":"14","author":"Conrad","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"24","key":"2024062807261001300_fcae131-B103","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198812153192401","article-title":"Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985)","volume":"319","author":"Smilkstein","year":"1988","journal-title":"N Engl J Med"},{"issue":"25","key":"2024062807261001300_fcae131-B104","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.2174\/092986711803414368","article-title":"Antioxidant therapy: Current status and future prospects","volume":"18","author":"Firuzi","year":"2011","journal-title":"Curr Med Chem"},{"issue":"9","key":"2024062807261001300_fcae131-B105","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-021-00233-1","article-title":"Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy","volume":"20","author":"Forman","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2024062807261001300_fcae131-B106","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3389\/fimmu.2020.00484","article-title":"Targeting inflammation driven by HMGB1","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"2024062807261001300_fcae131-B107","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.jvca.2008.08.005","article-title":"A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass","volume":"23","author":"Bennett-Guerrero","year":"2009","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"8","key":"2024062807261001300_fcae131-B108","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2165\/11318390-000000000-00000","article-title":"Matrix metalloproteinase inhibitors: A critical appraisal of design principles and proposed therapeutic utility","volume":"70","author":"Dorman","year":"2010","journal-title":"Drugs"},{"issue":"9","key":"2024062807261001300_fcae131-B109","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/cells8090984","article-title":"The rebirth of matrix metalloproteinase inhibitors: Moving beyond the dogma","volume":"8","author":"Fields","year":"2019","journal-title":"Cells"},{"issue":"5","key":"2024062807261001300_fcae131-B110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/rheumatology\/40.5.537","article-title":"Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis","volume":"40","author":"Hemmings","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2024062807261001300_fcae131-B111","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrneurol.2009.54","article-title":"Brain-derived neurotrophic factor in neurodegenerative diseases","volume":"5","author":"Zuccato","year":"2009","journal-title":"Nat Rev Neurol"},{"key":"2024062807261001300_fcae131-B112","doi-asserted-by":"crossref","first-page":"105281","DOI":"10.1016\/j.phrs.2020.105281","article-title":"Challenges of BDNF-based therapies: From common to rare diseases","volume":"162","author":"Miranda-Lourenco","year":"2020","journal-title":"Pharmacol Res"},{"issue":"5","key":"2024062807261001300_fcae131-B113","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1023\/A:1018940732550","article-title":"Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood\u2013brain barrier in vivo using vector-mediated peptide drug delivery","volume":"11","author":"Pardridge","year":"1994","journal-title":"Pharm Res"},{"issue":"2","key":"2024062807261001300_fcae131-B114","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0169-328X(95)00250-V","article-title":"Permeability at the blood\u2013brain and blood\u2013nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF","volume":"36","author":"Poduslo","year":"1996","journal-title":"Brain Res Mol Brain Res"},{"issue":"1","key":"2024062807261001300_fcae131-B115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40035-022-00279-0","article-title":"Brain-derived neurotrophic factor in Alzheimer\u2019s disease and its pharmaceutical potential","volume":"11","author":"Gao","year":"2022","journal-title":"Transl Neurodegener"},{"issue":"5","key":"2024062807261001300_fcae131-B116","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/art.33493","article-title":"Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus","volume":"64","author":"Bengtsson","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2024062807261001300_fcae131-B117","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13075-021-02573-0","article-title":"An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod","volume":"23","author":"Hesselstrand","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2024062807261001300_fcae131-B118","first-page":"e100115","article-title":"The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research","volume":"4","author":"Percie du Sert","year":"2020","journal-title":"BMJ Open Sci"},{"issue":"2","key":"2024062807261001300_fcae131-B119","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0023677217724823","article-title":"PREPARE: Guidelines for planning animal research and testing","volume":"52","author":"Smith","year":"2018","journal-title":"Lab Anim"},{"issue":"2","key":"2024062807261001300_fcae131-B120","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1172\/JCI109850","article-title":"Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone","volume":"66","author":"Scheld","year":"1980","journal-title":"J Clin Invest"},{"issue":"3","key":"2024062807261001300_fcae131-B121","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/infdis\/151.3.528","article-title":"Effects of ampicillin and corticosteroids on brain water content, cerebrospinal fluid pressure, and cerebrospinal fluid lactate levels in experimental pneumococcal meningitis","volume":"151","author":"Tauber","year":"1985","journal-title":"J Infect Dis"},{"issue":"15","key":"2024062807261001300_fcae131-B122","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1056\/NEJM198810133191502","article-title":"Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials","volume":"319","author":"Lebel","year":"1988","journal-title":"N Engl J Med"},{"issue":"3","key":"2024062807261001300_fcae131-B123","first-page":"301","article-title":"Magnetic resonance imaging and dexamethasone therapy for bacterial meningitis","volume":"143","author":"Lebel","year":"1989","journal-title":"Am J Dis Child"},{"issue":"22","key":"2024062807261001300_fcae131-B124","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJM199105303242201","article-title":"The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis","volume":"324","author":"Odio","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"2024062807261001300_fcae131-B125","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1542\/peds.44.4.503","article-title":"Dexamethasone in the treatment of acute bacterial meningitis: The effect of study design on the interpretation of results","volume":"44","author":"Belsey","year":"1969","journal-title":"Pediatrics"},{"issue":"1","key":"2024062807261001300_fcae131-B126","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1542\/peds.44.1.30","article-title":"Corticosteroids as an adjunct to treatment in bacterial meningitis. A controlled clinical trial","volume":"44","author":"DeLemos","year":"1969","journal-title":"Pediatrics"},{"key":"2024062807261001300_fcae131-B127","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s12879-016-1711-z","article-title":"Time to antibiotic therapy and outcome in bacterial meningitis: A Danish population-based cohort study","volume":"16","author":"Bodilsen","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2024062807261001300_fcae131-B128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756285609337975","article-title":"Pathophysiology and treatment of bacterial meningitis","volume":"2","author":"Hoffman","year":"2009","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"2024062807261001300_fcae131-B129","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1128\/CMR.00012-08","article-title":"Animal models of Streptococcus pneumoniae disease","volume":"21","author":"Chiavolini","year":"2008","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"2024062807261001300_fcae131-B130","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/319271","article-title":"Experimental pneumococcal meningitis in mice: A model of intranasal infection","volume":"183","author":"Zwijnenburg","year":"2001","journal-title":"J Infect Dis"},{"issue":"2","key":"2024062807261001300_fcae131-B131","first-page":"133","article-title":"Development of hematogenous pneumococcal meningitis in adult mice: The role of TNF-alpha","volume":"32","author":"Tsao","year":"2002","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"1","key":"2024062807261001300_fcae131-B132","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2334-12-71","article-title":"Characterization of a pneumococcal meningitis mouse model","volume":"12","author":"Mook-Kanamori","year":"2012","journal-title":"BMC Infect Dis"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcae131\/57221149\/fcae131.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/6\/3\/fcae131\/58265475\/fcae131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/6\/3\/fcae131\/58265475\/fcae131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T03:28:15Z","timestamp":1719545295000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcae131\/7644484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcae131","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024]]},"published":{"date-parts":[[2024]]},"article-number":"fcae131"}}